Hashimoto, Masashi
Kuroda, Shinji http://orcid.org/0000-0002-4484-1253
Kanaya, Nobuhiko
Kadowaki, Daisuke
Yoshida, Yusuke
Sakamoto, Masaki
Hamada, Yuki
Sugimoto, Ryoma
Yagi, Chiaki
Ohtani, Tomoko
Kumon, Kento
Kakiuchi, Yoshihiko
Yasui, Kazuya
Kikuchi, Satoru
Yoshida, Ryuichi
Tazawa, Hiroshi http://orcid.org/0000-0003-4658-1050
Kagawa, Shunsuke http://orcid.org/0000-0002-3610-8211
Yagi, Takahito
Urata, Yasuo
Fujiwara, Toshiyoshi
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP16K19893, JP20K17690)
Japan Agency for Medical Research and Development (20ck0106569)
Article History
Received: 20 September 2023
Revised: 3 January 2024
Accepted: 10 January 2024
First Online: 5 February 2024
Competing interests
: Yasuo Urata is President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-702. Hiroshi Tazawa and Toshiyoshi Fujiwara are consultants of Oncolys BioPharma, Inc. The remaining authors declare no competing interests.
: The study using clinical samples of pancreatic cancer patients was approved by the institutional review board of Okayama University (No. 2110-017). All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of Okayama University.
: Not applicable.